About Legumain
Legumain (LGMN) is a protein
from Homo sapiens identified by UniProt accession
Q99538, 433 residues long.
MolForge cross-references it against 0 known binders and
569 disease associations.
Target properties
| Protein name | Legumain |
|---|
| UniProt accession | Q99538 |
|---|
| Gene | LGMN |
|---|
| Organism | Homo sapiens |
|---|
| Length | 433 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (569)
Diseases linked to this target (Open Targets).
- lung adenocarcinoma · score 0.23
- head and neck squamous cell carcinoma · score 0.23
- serum metabolite measurement · score 0.23
- blood protein measurement · score 0.19
- endometrial cancer · score 0.18
- cutaneous melanoma · score 0.15
- gastric adenocarcinoma · score 0.13
- pathological myopia · score 0.11
- Myopia · score 0.11
- neoplasm · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q99538-F1 | alphafold | PREDICTED | 94.08 | — |
Amino-acid sequence (433 residues)
MVWKVAVFLS VALGIGAVPI DDPEDGGKHW VVIVAGSNGW YNYRHQADAC HAYQIIHRNG IPDEQIVVMM YDDIAYSEDN PTPGIVINRP NGTDVYQGVP KDYTGEDVTP QNFLAVLRGD AEAVKGIGSG KVLKSGPQDH VFIYFTDHGS TGILVFPNED LHVKDLNETI HYMYKHKMYR KMVFYIEACE SGSMMNHLPD NINVYATTAA NPRESSYACY YDEKRSTYLG DWYSVNWMED SDVEDLTKET LHKQYHLVKS HTNTSHVMQY GNKTISTMKV MQFQGMKRKA SSPVPLPPVT HLDLTPSPDV PLTIMKRKLM NTNDLEESRQ LTEEIQRHLD ARHLIEKSVR KIVSLLAASE AEVEQLLSER APLTGHSCYP EALLHFRTHC FNWHSPTYEY ALRHLYVLVN LCEKPYPLHR IKLSMDHVCL GHY
Explore Legumain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets